bpc-157 clinical trials humans and the Difference Between an Evidence Gap and a Cover-Up: What the entire human evidence base actually looks like, and the questions to ask next. — WellFounded bpc-157 clinical trial humans human

Peptide origin / Partial sequence of human gastric protein BPC, isolated from gastric juice Molecular weight / Approximately 1,419 Da (15 amino acids) Common off-label oral dose / 250 to 500 mcg twice daily, taken on an empty stomach Common off-label subcutaneous dose / 200 to 300 mcg once or twice daily near the affected area or abdominally Evidence level / Preclinical only (GRADE: very low certainty for human GI healing) Key preclinical finding / Accelerated gastric ulcer healing in rats within 24 to 72 hours across multiple models Route preference for GI targets / Oral administration, based on topical mucosal contact rationale Safety profile in humans / Largely unknown

Compatible with Combination Protocols : Frequently studied alongside GLP-1 receptor agonists like semaglutide to explore multi-hormone strategies for appetite and metabolic regulation

Stangl Law Offices, S.C.

Cancer Patients Some integrative oncologists use high-dose IV vitamin C as an adjunct therapy in cancer treatment